Pancreatic, thyroid, and other endocrine cancers
Drug Name
- ABRAXANE
- Active Surveillance: Is it an Appropriate Approach for Thyroid Cancer?
- AFINITOR
- AZEDRA
- CAPRELSA
- COMETRIQ
- Cumulative Risk for Thyroid Cancer After Initial Benign Thyroid Biopsy
- Doxorubicin HCl
- Doxorubicin HCl Solution
- FFPE Tissue Specimens Deemed Adequate for Molecular Studies: NCI-SEER
- Fluorouracil
- GEMZAR
- High Response Rate for Patients With High-Grade Neuroendocrine Cancer Receiving Dual Immune Checkpoint Blockade
- INFUGEM
- LENVIMA
- LUTATHERA
- LYSODREN
- MEKINIST
- Mitomycin
- NEXAVAR
- Once-Weekly Exenatide Treatment Does Not Increase Risk for Medullary Thyroid Carcinoma
- ONIVYDE
- Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial
- SOMATULINE DEPOT
- SUTENT
- SYNTHROID
- TAFINLAR
- TARCEVA
- THYROGEN
- Thyroid Cancer: Individualized Follow-Up Curtails Unnecessary Tests
- TIROSINT-SOL
- UNITHROID
- VITRAKVI
- VITRAKVI ORAL SOLUTION
- ZANOSAR
